References
- Harris EN. Syndrome of the black swan. Br. J. Rheumatol.26, 324–326 (1987).
- Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum.42, 1309–1311 (1999).
- McNeil HP, Simpson RJ, Cherterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes lipid binding inhibitor of coagulation: β2 glycoprotein I (apolipoprotein H). Proc. Natl Acad. Sci. USA87, 4120–4124 (1990)
- Atsumi T, Koike T. Clinical relevance of antiprothrombin antibodies. Autoimmun. Rev.1, 49–53 (2002).
- Lin WS, Chen PC, Yang CD et al. Some antiphospholipid antibodies recognize conformational epitopes shared by β2 glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum.56, 1638–1647 (2007).
- Chen XX, Gu YY, Li SJ et al. Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J. Immunol.178, 5351–5356 (2007).
- Cesarman-Maus G, Rios-Luna NP, Deora AB et al. Autoantibodies against the fibrinolytic receptor, annexin A2, in antiphospholipid syndrome. Blood107, 4375–4382 (2006).
- Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in SLE: striking associations with the presence of circulating lupus anticoagulant. Br. Med. J.287, 1021–1023 (1983).
- Ginsburg KS, Liang MH, Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann. Intern. Med.117, 997–1002 (1992).
- McClain MT, Arbuckle MR, Heinlen LD et al. The prevalence, onset and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum.50, 1226–1232 (2004).
- Asherson RA. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid (Asherson’s) syndrome. Immunobiology210, 727–733 (2005).
- Moroni G, Ventura D, Riva P et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am. J. Kidney Dis.43, 28–36 (2004).
- Moroni G, Tantardini F, Galleli B. et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am. J. Kidney Dis.45, 903–911 (2005).
- Miyakis S, Lockshin MD, Atsumi I et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost.4, 295–306 (2006).
- Gleason CB, Stoddard MF, Wagner SG et al. A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin negative systemic lupus erythematosus. Am. Heart J.125, 1123–1129 (1993).
- Toubi E, Krause I, Fraser A et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin. Exp. Rheumatol.23, 499–504 (2005).
- Atsumi T, Furukawa S, Amengual O, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. Lupus14, 499–504. (2005).
- Sherer Y, Hassin S, Shoenfeld Y et al. Transverse myelitis in patients with antiphospholipid antibodies – the importance of early diagnosis and treatment. Clin. Rheumatol.21, 207–210 (2002).
- Al-Matar M, Jaimes J, Malleson P. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics2, 107–108 (2000).
- Hughes GR. Migraine, memory loss, and ‘multiple sclerosis’. Neurological features of the antiphospholipid (Hughes’) syndrome. Postgrad. Med. J.79, 81–83 (2003).
- Cimaz R, Meroni PL Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus15, 191–197 (2006).
- Tektonidou MG, Malagari K, Vlachoyiannopoulos PG et al. Asyptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging. Arthritis Rheum.48, 732–736 (2003).
- Gharavi AE, Pierangeli SS, Harris EN. Origin of antiphospholipid antibodies. Rheum. Dis. Clin. North Am.27, 551–563 (2001).
- Blank M, Asherson RA, Cervera R et al. Antiphospholipid syndrome infectious origin. J. Clin. Immunol.24, 12–23 (2004).
- Branch DW, Dudley DJ, Mitchell MD et al. Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. Am. J. Obstet. Gynecol.163, 210–216 (1990).
- Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome in naïve mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc. Natl Acad. Sci. USA88, 3069–3073 (1991).
- Pierangeli SS, Colden-Stanfield M, Liu X et al. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation99, 1997–2000 (1999).
- Jankowski M, Vreys I, Wittevrongel C et al. Thrombogenicity of β2 glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood101, 157–162 (2003).
- Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus7, S114–S119 (1998).
- Fishman P, Falach-Vaknine E, Zigelman R et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J. Clin. Invest.91, 1834–1837 (1993).
- Holers VM, Girardi G, Mo L et al. C3 activation is required for anti-phospholipid antibody-induced fetal loss. J. Exp. Med.195, 211–220 (2002).
- Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann. Rheum. Dis.61, 46–50 (2002).
- Pierangeli SS, Girardi G, Vega-Ostertag ME et al. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum.52, 2120–2124 (2005).
- Fischetti F, Durigutto P, Pellis V et al. Thrombus formation induced by antibodies to β2 glycoprotein I is complement-dependent and requires a priming factor. Blood106, 2340–2346 (2005).
- Khamashta MA, Cuadrado MJ, Mujic T et al. The management of thrombosis in the antiphospholipid antibody syndrome. N. Engl. J. Med.332, 993–997 (1995).
- Krnic-Barrie S, O’Connor CR, Looney SE et al. A retrospective review of 61 patients with antiphospholipid syndrome. Arch. Intern. Med.157, 2101–2108 (1997).
- Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N. Engl. J. Med.349, 1133–1138 (2003).
- Finazzi G, Marchioli R, Brancaccio V et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J. Thromb. Haemost.3, 848–853 (2005).
- Erkan D, Yazici Y, Peterson MG et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford)41, 924–929 (2002).
- Jancinova V, Nosal R, Petrikova M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb. Res.74, 494–504 (1994).
- Goldman FD, Gilman AL, Hollenback C et al. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood95, 3460–3466 (2000).
- McCarty GA, Cason TE. Use of hydroxychloroquine in antiphospholipid antibody syndrome at three academic rheumatology units over two years: improvement in antibody titer and symptoms management. In: 7th International Congress on SLE and Related Conditions. Abstract Book. NY, USA (2004). M17A (Abstract).
- Erkan D, Lockshin MD. New therapies for antiphospholipid syndrome. Rheum. Dis. Clin. North Am.32, 129–148 (2006).
- Garcia DA, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood110(9), 3122–3127 (2007).
- Erkan D, Ortel TL, Lockshin MD. Warfarin in antiphospholipid syndrome – time to explore new horizons. J. Rheumatol.32, 208–212 (2005).
- Erkan D, Harrison MJ, Levy R et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome. Arthritis Rheum.56, 2382–2391 (2007).
- Erkan D. The relation between antiphospholipid syndrome-related pregnancy morbidity and non-gravid vascular thrombosis: a review of the literarture and management strategies. Curr. Rheum. Rep.4, 379–386 (2002).
- Clark AL, Branch DW, Silver RM et al. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy. Obstet. Gynecol.93, 437–441 (1999).
- Spinnato JA, Clark AL, Pierangeli SS et al. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am. J. Obstet. Gynecol.172, 690–694 (1995).
- Bucciarelli S, Espinosa G, Cervera R et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum.54, 2568–2576 (2006).
- Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum.48, 3320–3327 (2003).
- Kazatchkine MD and Kaveri SV. 2001. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin N. Engl. J. Med.345, 747–755 (2001).
- Zaidan R, Al Moallem M, Wani BA et al. Thrombosis complicating high dose intravenous immunoglobulin: report of three cases and review of the literature. Eur. J. Neurol.10, 367–372 (2003).
- Brown HC, Ballas ZK. Acute thromboembolic events associated with intravenous immunoglobulin sinfusion in antibody-deficient patients. J. Allergy Clin. Immunol.112, 797–799 (2003).
- Krause I, Wu R, Sherer et al. in vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations – a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transf. Med.12, 133–139 (2002).
- Erdozain JG, Ruiz-Irastorza G, Egubide MV et al. Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica89, ECR34 (2004).
- Ehresmann S, Arkfeld D, Shinada S et al. A novel therapeutic approach for catastrophic antiphospholipid syndrome. (CAPS) when conventional therapy with anticoagulants and steroids were unsuccessful. Ann. Rheum. Dis.64(Suppl. 1), 70 (2004). (Abstract FR10278).
- Tommasino C, Fossati G, Saulino A et al. Short-term lack of efficacy of rituximab in a thrombocytopaenic patient with primary antiphospholipid syndrome. Thromb. Res.114(5–6), 652 (2004).
- Khamashta MA, Harris EN, Gharavi AE et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann. Rheum. Dis.47, 849–854 (1988).
- Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb. Haemost.73, 529–534 (1995).
- Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost.87, 518–522 (2002).
- Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation96, 4380–4384 (1997).
- Hulstein JJ, Lenting PJ, De Laat B et al. β2 glycoprotein I inhibits von Willebrand factor-dependent platelet adhesion and aggregation. Blood110, 1483–1491 (2007).
- Martinuzzo ME, Maclouf J, Carreras LO et al. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb. Haemost.70, 667–671 (1993).
- Forastiero R, Martinuzzo M, Carreras LO, Maclouf J. anti-β2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb. Haemost.79, 42–45 (1998).
- Robbins DL, Leung S, Miller-Blair DJ, Ziboh V. Effect of anticardiolipin/β2 glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J. Rheumatol.25, 51–56 (1998).
- Opara E, Robbins DL, Ziboh VA. Cyclic-AMP agonists inhibit antiphospholipid/β2 glycoprotein I induced synthesis of human platelet thromboxane A2 in vitro. J. Rheumatol.30, 55–59 (2003).
- Vega-Ostertag M, Harris EN, Pierangeli SS. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum.50, 2911–2919 (2004).
- Lutters BC, Derksen RH, Tekelenburg WL et al. Dimers of β2 glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2’. J. Biol. Chem.278, 33831–33838 (2003).
- Shi T, Giannakopulos B, Yan X et al. anti-β2 glycoprotein I antibodies in complex with β2 glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib/IX-V. Arthritis Rheum.54, 2558–2567 (2006).
- Simantov E, LaSala J, Lo SK et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest.96, 2211–2219 (1995).
- Del Papa N, Guidali L, Spatola L et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III; β2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules. Clin. Exp. Rheumatol.13, 179–185 (1995).
- Del Papa N, Guidali L, Sala A et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-β2 glycoprotein I antibodies react in vitro with endothelial cells through adherent β2 glycoprotein I and induce endothelial activation. Arthritis Rheum.40, 551–561 (1997).
- Meroni PL, Raschi E, Testoni C et al. Antiphospholipid antibodies and the endothelium. Rheum. Dis. Clin. North Am.27, 587–602 (2001).
- Pierangeli SS, Espinola RG, Liu X et al. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ. Res.88, 245–250 (2001).
- Espinola RG, Liu X, Colden-Stanfield M et al. E-selectin mediated pathogenic effects of antiphospholipid antibodies. J. Thromb. Haemost.1, 843–848 (2002).
- Cuadrado MJ, Lopez-Pedrera C, Khamashta MA et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum.40, 834–841 (1997).
- Amengual O, Atsumi T, Khamashta MA et al. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb. Haemost.79, 276–281 (1998).
- Dobado-Barrios M, Lopez-Pedrera C, Velasco F et al. Increased levels of TF mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb. Haemost.82, 1578–1582 (1999).
- Martini F, Farsi A, Gori AM et al. Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus. Lupus5, 206–211 (1996).
- Reverter JC, Tassies D, Font J et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum.41, 1420–1427 (1998).
- Forastiero RR, Martinuzzo M, De Larranaga G. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprous related antiphospholipid antibodies. Lupus14, 129–136 (2005).
- Kornberg A, Blank M, Kaufman S et al. Induction of tissue factor-like activity in monocytes by antiphospholipid antibodies. J. Immunol.153, 1328–1332 (1994).
- Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood104, 2353–2358 (2004).
- Ferrara DE, Liu X, Espinola RG et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum.48, 3272–3279 (2003).
- Ferrara DE, Swerlick R, Casper K et al. Fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J. Thromb. Haemost.2, 1558–1563 (2004).
- Bohgaki M, Atsumi I, Yamashita Y et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-β2 glycoprotein I antibodies. Int. Immunol.16, 1632–1641 (2004).
- Dunoyer-Geindre S, deMoerloose P, Galve-de Rochemonteiz B et al. NF-κB is an essential intermediate in the activation of endothelial cells by anti-β2 glycoprotein I antibodies. Thromb. Haemost.88, 851–857 (2002).
- Vega-Ostertag M, Casper K, Swerlick R et al. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum.52, 1545–1554 (2005).
- Simoncini S, Sapet C, Camoin-Jau L et al. Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. Int. Immunol.17, 489–500 (2005).
- López-Pedrera C, Buendia P, Cuadrado MJ et al. Antiphopholipid antibodies from patients with the antiphospholipid syndrome induce tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via p38 mitogen activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum.54, 301–311 (2006).
- Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J. Thromb. Haemost.5, 1828–1834 (2007).
- Montiel-Manzano G, Romay-Penabad E, Papalardo de Martinez E et al. in vivo effects of an inhibitor of nuclear factor-k(-) B on thrombogenic properties of antiphospholipid antibodies. Ann. NY Acad. Sci.1108, 540–553 (2007).
- Del Papa N, Sheng YH, Raschi E et al. Human β2 glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipids binding and offers epitopes for anti-β2 glycoprotein I antibodies. J. Immunol.160, 5572–5578 (1998).
- Vega Ostertag M, Liu X, Henderson V et al. A peptide that mimics the Vth region of β2 glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus15, 358–365 (2006).
- Ioannou J, Harper T, Romay-Penabad Z et al. Domain I of β2 glycoprotein I ameliorates thrombosis induced by antiphospholipid antibodies in mice. Abstract. Arthritis Rheum.54(Suppl.), S559 (2006).
- Ma K, Simantov R, Zhang J et al. High affinity binding of β2 glycoprotein I to human endothelial cells is mediated by annexin II. J. Biol. Chem.275, 15541–15548 (2000).
- Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/β2 glycoprotein I antibodies. Blood105, 1964–1969 (2005).
- Raschi E, Testoni C, Bosisio D et al. Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood101, 3495–3500 (2003).
- Pierangeli SS, Vega-Ostertag ME, Raschi E et al. Toll like receptor 4 is involved in antiphospholipid-mediated thrombosis: in vivo studies. Ann. Rheum. Dis.66(10), 1327–1333 (2007).
- Borghi M, Raschi E, Scurati C et al. Effects of Toll-like receptor antagonist and anti-annexin A2 antibodies on binding and activation of decidual cells by anti-β2 glycoprotein I antibodies (abstract). J. Thromb. Haemost.5(Suppl. 2), P-T-427 (2007).
- Romay-Penabad Z, Liu X, Montiel-Manzano G et al. C5a receptor-deficient micer are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies. Ann. NY Acad. Sci.1108, 554–566 (2007).
- Munakata Y, Saito T, Matsuda K et al. Detection of complement-fixing antiphospholipid antibodies in association with thrombosis. Thromb. Haemost.83, 728–731 (2000).
- Carbone J, Orera M, Rodriguez-Mahou M et al. Immunological abnormalities in primary APS evolving into SLE: 6 years follow-up in women with repeated pregnancy loss. Lupus8, 274–278 (1999).
- Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin. Exp. Immunol.10, 455–460 (1992).
- Gharavi AE, Pierangeli SS, Harris EN. Viral origin of antiphospholipid antibodies: endothelial cell activation and thrombus enhancement by CMV peptide-induced aPL antibodies. Immunobiology207, 37–42 (2003).
- Gharavi AE, Pierangeli SS, Espinola RG et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum.46, 545–552 (2002).
- Gharavi AE, Vega-Ostertag M, Espinola RG et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus13, 17–23 (2004).
- Blank M, Krause I, Fridkin M et al. Bacterial induction of autoantibodies to β2 glycoprotein I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Invest.109, 797–804 (2002).
- Blank M, Asherson RA, Cervera R et al. Antiphospholipid syndrome infectious origin. J. Clin. Immunol.24, 12–23 (2004).
- Gharavi EE, Chaimovich H, Cucurull E et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus8, 449–455 (1999).
- Pierangeli SS, Blank M, Liu X et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J. Autoimmun.22, 217–225 (2004).